A phase 1, randomized, placebo-controlled, double-blinded study to determine safety, tolerability, and pharmacokinetics of GDC-0276 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2017
At a glance
- Drugs GDC 0276 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 08 Jan 2017 Status changed from recruiting to completed, as reported by a Xenon Pharmaceuticals media release.
- 10 Nov 2015 According to a Xenon Pharmaceuticals media release, patient enrolment in this trial is expected to be completed by the end of 2015.
- 28 May 2015 According to Xenon Pharmaceuticals media release, patient enrollment is expected to complete in the second half of 2015